NEW YORK– Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced an expanded collaboration with AstraZeneca focused on refining a biologics modeling solution with the aim of speeding up the development of antibody and protein-based therapeutic candidates. The multi-year agreement extends an existing collaboration in […]
Three-year deal will enable broader chemical exploration and accelerate advanced molecular modeling across internal and collaborative programs NEW YORK — Schrödinger, Inc. (Nasdaq: SDGR) today announced it has entered into a three-year agreement with Google Cloud to substantially increase the speed and capacity of its physics-based computational platform for drug discovery. As part of the […]
Tim Hohm to further develop Optibrium’s sales and business strategy for global market expansion CAMBRIDGE, UK – Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Tim Hohm as Director of Commercial Strategy and Business Development. Tim will be responsible for leading the Company’s commercial strategy and sales processes, with a […]
NEW YORK– Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its initial public offering of 13,664,704 shares of common stock at a public offering price of $17.00 per share, which includes 1,782,352 additional shares of […]
NEW YORK–Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the pricing of its initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $202.0 […]
NEW YORK — Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs. The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of […]
Partnership will advance both firms’ positions in the field of molecular dynamics-based drug discovery NEW YORK and SANTA FE, N.M. — Redesign Science and OpenEye Scientific are pleased to announce that they have entered into a strategic partnership to integrate OpenEye’s pioneering Orion computational platform into Redesign’s drug discovery platform. The practice of drug discovery has radically transformed […]
BOSTON – Scilligence, an innovation leader of unified informatics platform for biologics and small molecules drug R&D, has partnered with Certara to enable advanced data analysis and visualization capabilities. The companies worked together to integrate Certara’s D360 with Scilligence’s RegMol system. The partnership will help current and future clients to better visualize their scientific research data. […]
New extension enables researchers to explore the REAL Space of 11 billion readily accessible compounds directly from StarDrop CAMBRIDGE, UK, KIEV, UKRAINE and SANKT AUGUSTIN, GERMANY – Optibrium™, BioSolveIT™ and Enamine™, leading providers of software and services for drug discovery, today announce a three-way collaboration enabling efficient search of Enamine’s REAL Space directly from within Optibrium’s […]
Collaboration between drug companies and contract research partners drives innovation in evolving business environment. Columbus, Ohio – CAS, a division of the American Chemical Society, announced today that leading contract research, development and manufacturing organization (CRO/CDMO) BioDuro has signed a five-year agreement for SciFindern. This agreement provides enterprise-wide access to the most advanced scientific information solution […]
Pay Invoice
Latest Blogs
-
Automation Provides a Boost for Sample Prep Instrument Market Growth
August 25, 2026 11:49 am
-
SDi Predicts a Recovery Amid Headwinds
July 24, 2026 2:51 pm
-
EU Roadmap Provides Further Impetus for New Approach Methodologies
June 29, 2026 12:56 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
